Debate: Pausing AI would kill via delayed drugs and slower economic growth, argues researcher
panickssery · x · 2026-09-28
In a reply to @hilbertspaess, panickssery argues that medical AI isn't the main bottleneck to medical progress, but that any delay—even a prudent pause-style regulation—costs lives through later drug availability and, more importantly, slower explosive economic growth. The interlocutor counters that a global slowdown is in everyone's interest: datacenters curing rare diseases and doing alignment research instead of self-improving, giving humans time to digest breakthroughs. A substantive clash on AI pacing as a collective action problem.
Related event: Debate over 'global slowdown': Is delayed growth deadlier than AI?(3 posts)→
More from AGI Musings
- Next Token #004: Opus 5.5's creative leap, Muse hype, and does China have AI PMs? — vista8 · 2026-09-28
- Andrew Yang warns AI will crush millions of jobs; Theo Jaffee pushes back with 200 years of automation history — herbiebradley · 2026-09-28
- Critic slams 'relevance-chasing' influencers reinventing themselves as AI prophets — PierceLilholt · 2026-09-28
- Beff Jezos slams AI safety establishment: create risks, then sell tokens as insurance — beffjezos · 2026-09-28
- Claude Code creator Boris Cherny: bet on general models, skip fine-tuning — rohanpaul_ai · 2026-09-28
- Sarvam RL lead leaves after 2.5 years to build verification for AI-accelerated science — sumanthd17 · 2026-09-28